menu
    • menu
    [{"orgOrder":0,"company":"Corsair Pharma","sponsor":"Junson Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Treprostinil Prodrug","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsair Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Patch","sponsorNew":"Corsair Pharma \/ Junson Capital","highestDevelopmentStatusID":"6","companyTruncated":"Corsair Pharma \/ Junson Capital"},{"orgOrder":0,"company":"Corsair Pharma","sponsor":"InstantGMP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Treprostinil Prodrug","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsair Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corsair Pharma \/ InstantGMP","highestDevelopmentStatusID":"6","companyTruncated":"Corsair Pharma \/ InstantGMP"}]

    Find Clinical Drug Pipeline Developments & Deals by Corsair Pharma

    Menu

    Corsair Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Corsair Pharma

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Corsair Pharma

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Prodrug

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : InstantGMP

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Corsair Pharma Partners with InstantGMP® to Ensure Quality for Clinical Trials

                            Details : The partmership aims to create improved treatment options for patients with complex medical needs, including PAH treatment with its first product candidate CO-254, a prodrug of treprostinil.

                            Product Name : CO-254

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 28, 2025

                            Lead Product(s) : Treprostinil Prodrug

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : InstantGMP

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Corsair Pharma

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Corsair Pharma

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Prodrug

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Junson Capital

                            Deal Size : $23.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hyper...

                            Details : The proceeds will support the clinical advancement of Corsair’s lead product candidate, a prodrug of treprostinil delivered in a proprietary transdermal patch to treat Pulmonary Arterial Hypertension (PAH).

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2023

                            Lead Product(s) : Treprostinil Prodrug

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Junson Capital

                            Deal Size : $23.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth